

CORRELATION OF C-REACTIVE PROTEIN AND COPD SEVERITY

Nena Milačić¹, Bojan Milačić², Maja Milojković³, Srdjan Ljubisavljević³, Sanja Vodopić⁴,
Mirha Hasanbegović⁵ and Marija Đurović⁶

¹Clinical Department of Pulmonology, ²Clinical Department of Thoracic Surgery, Clinical Centre of Montenegro, Podgorica, Montenegro; ³University Department for Pathophysiology, School of Medicine, University of Niš, Niš, Serbia; ⁴Clinical Department of Neurology, Clinical Centre of Montenegro; ⁵Clinical Department of Internal Medicine, Pljevlja General Hospital, Pljevlja; ⁶Clinical Department of Internal Medicine, Clinical Centre of Montenegro, Podgorica, Montenegro

SUMMARY – Chronic obstructive pulmonary disease (COPD) is a progressive pulmonary disease characterized by systemic inflammation. The aim of this study was to correlate the parameters of systemic inflammation, C-reactive protein (CPR) and total leukocyte count, with clinical indicators of the disease. Our study included 157 COPD patients, both outpatients and those hospitalized at the Knez Selo Department of Pulmonology of the Niš Clinical Centre during a six-month period, while in the phase of disease exacerbation. The symptoms of COPD in each patient were estimated by the COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scale. The parameters of pulmonary function (FEV1 and FVC), acid-base status, body mass index, history of exacerbation and comorbidities were also evaluated. The level of CRP, but not leukocytes, showed significant correlation with the severity of clinical presentation according to GOLD classification. The higher the CRP concentration, the higher was the disease severity determined according to GOLD classification ($p < 0.001$). There was no statistically significant difference in CRP level and leukocyte count according to comorbidities ($p = 0.29$). The level of CRP was higher in patients with a high CAT score and mMRC scale ($p < 0.001$). The same trend was observed for leukocyte count when compared with CAT results, but not when correlated to mMRC scale. The level of CRP during COPD exacerbation can be an independent predictor of the disease severity and paraclinical findings.

Key words: *Pulmonary disease; Chronic obstructive pulmonary disease – diagnosis; Chronic obstructive pulmonary disease – classification; C-reactive protein; Respiratory function tests; Severity of illness index; Surveys and questionnaires*

Introduction

Chronic obstructive pulmonary disease (COPD) is a common and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammato-

ry response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients^{1,2}. COPD is currently the fourth leading cause of death and a considerable economic and social burden worldwide, especially in underdeveloped countries³⁻⁶.

Diagnostic and therapeutic parameters used to evaluate COPD are based on assessment of symptoms, severity of airflow limitation, history of exacerbations, and comorbidities². The COPD Assessment Test (CAT) is a short, easy-to-complete health status

Correspondence to: *Nena Milačić, MD*, Department of Pulmonology, Clinical Centre of Montenegro, Ljubljanska bb, Podgorica, Montenegro

E-mail: nenamilacic75@gmail.com

Received July 6, 2015, accepted November 24, 2015

tool that has been developed to help patients and their clinicians assess and quantify the symptoms and impacts of COPD^{7,8}. On the other hand, a weak breath is the most common symptom reported by long-term COPD patients⁹, and it significantly reduces the quality of life^{10,11}. Therefore, it is necessary to estimate patients' airflow and thus modified Medical Research Council (mMRC) dyspnea scale is used¹². It is simple to use with a predictive value and it correlates with clinical and functional pulmonary parameters¹³⁻¹⁵.

Numerous studies have confirmed that acute exacerbations of COPD imply increased levels of C-reactive protein (CRP), as well as modification of other inflammatory parameters¹⁶⁻¹⁸.

The aim of this study was to correlate the inflammation parameters of CRP and leukocyte count with clinical indicators of COPD (disease symptoms assessed by CAT and mMRC dyspnea scale, history of exacerbation and comorbidities, and blood gas analysis results). To our knowledge, no similar study has been conducted in Serbia and Montenegro to date.

Patients and Methods

This prospective study was conducted in the Niš Clinical Centre and was approved by the institution

Ethics Committee. Before taking part in the research, a written consent was obtained from each patient. The research included 157 patients (115 men and 45 women) suffering from COPD, both outpatients and those hospitalized at the Knez Selo Department of Pulmonology of the Niš Clinical Centre during a six-month period (from November to May 2013). Patients diagnosed with bronchial asthma, pneumonia and decompensated cardiomyopathy were excluded, as well as those who had suffered myocardial infarction in the last 6 weeks. Patients included in the study were experiencing an exacerbation of the disease.

The diagnosis of COPD was made based on GOLD guidelines². Inclusion criteria were postbronchodilation test ratio of the forced expiratory volume in the first second (FEV1) and the forced vital capacity (FVC) below 70%. The questionnaire used for estimation of COPD-CAT and mMRC dyspnea scale, as well as spirometric parameters were obtained during first outpatient or hospital treatment. The questionnaires were translated and back translated into Montenegrin language. All patients filled them in by themselves. Doctors did assist patients but did not suggest any answer.

Blood analysis was done in all patients. Spirometric parameters, FEV1 and FVC, were obtained using

Table 1. General and demographic characteristics of patients

Variable		N	%
Gender	Male/Female	115/42	73.2/26.8
Smoking habit	Non smokers	25	15,9
	Smokers	68	43,3
	Ex smokers	64	40,8
Exacerbations	Rare/Frequent	42/115	26.8/73.2
Age		67.76±9.39	68.00 (41.00-89.00)
BMI		26.61±6.28	25.88 (15.59-57.48)
FEV1		1.26±0.54	1.13 (0.33-2.87)
FEV1%		47.08±14.93	45.50 (16.60-79.90)
FVC		2.34±0.88	2.25 (0.68-5.03)
FVC%		69.38±17.80	67.50(28.90-105.80)
CRP		25.09±29.72	11.60 (1.20-110.00)
Leukocyte count		9.06±3.08	8.30 (3.50-18.60)

BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; FEV1% = FEV1/FVC ratio; FVC% = percent predicted forced vital capacity; CRP = C-reactive protein

Table 2. Patient characteristics in relation to GOLD classification

	GOLD 2	GOLD 3	GOLD 4	p
	n=60	n=79	n=18	
Age (yrs)	67.67±9.49	68.29±9.85	65.78±6.84	0.592
Gender (M/F)	43/17	58/21	23.66+/-5.33	0.875
BMI	28.18±7.17	26.08±5.43	23.66±5.33	0.015
Exacerbation	1.55±1.57	5.44±2.62	9.83±1.69	<0.001
FEV1	1.75±0.52	1.02±0.25	0.67±0.12	<0.001 ^a
CAT	17.98±6.37	27.94±6.34	34.89±2.76	<0.001 ^b
mMRC	1.33±0.71	2.52±0.90	3.67±0.48	<0.001 ^b
CRP	9.34±14.14	26.74±32.66	38.79±27.78	0.006 ^b
Leukocyte count	8.99±3.64	8.67±2.76	10.38±3.18	0.264 ^b

^aANOVA; ^bKruskal-Wallis test; BMI = body mass index; FEV1 = forced expiratory volume in 1 second; CAT = COPD Assessment Test; mMRC = modified Medical Research Council scale; CRP = C-reactive protein

the Erich Jaeger Masterlab (Germany) spirometric apparatus. Electrocardiography, chest radiography, information on the disease duration, comorbidities and exacerbations in previous year were obtained from the patients.

Statistics

Demographic variables (i.e. gender, age and smoking status) as well as clinical determinants were summarized in order to characterize the study population. Statistical analysis included descriptive statistics, Kolmogorov-Smirnov test, t-test, ANOVA, Kruskal Wallis test and regression analysis. The value of p less than 0.05 was considered statistically significant. The SPSS version 16.0 statistical program was used on data analysis.

Results

Table 1 summarizes demographic and clinical characteristics of study patients. The study was performed on 157 patients, mainly male (n=115) and smokers (n=68), mean age 67.76±9.39. Patients with a more severe form of COPD, i.e. those with a higher class of disease severity according to GOLD, had much more frequent exacerbations, higher CAT score and higher mMRC dyspnea score (p<0.001). CRP showed significant correlation with the severity of clinical presentation. The higher the CRP level, the higher was the class of disease severity accord-

ing to GOLD (p=0.005). These data are presented in Table 2.

Post hoc analysis determined that patients without comorbidities had a statistically significantly lower body mass index (BMI) in comparison to both patients with two or less comorbidities and patients with three or more comorbidities (p=0.01 both). There was no statistically significant difference in CRP level and leukocyte count according to comorbidities. The values of FEV1 (L), FVC (L) and FVC (%) decreased statistically significantly with the increase of comorbidities (p=0.028, p=0.002 and p=0.005, respectively). These results are shown in Table 3.

Patients with a high CAT score had statistically more frequent exacerbations (p<0.001). BMI was statistically significantly lower in patients with a high CAT score (p=0.02). CRP value was statistically significantly higher in patients with a high CAT score (p<0.001). Leukocyte count was statistically significantly higher in patients with a high CAT score (p=0.002). These results are summarized in Table 4.

Patients with a high CAT score had significantly lower values of FEV1 (L), FEV1%, FVC (L) and FVC% (p<0.001 all), and lower values of partial oxygen pressure (pO₂; p=0.016), bicarbonate (HCO₃; p=0.025) and oxygen saturation (sO₂; p=0.023). The values of partial carbon dioxide pressure (pCO₂) in arterial blood were statistically significantly higher in patients with a high CAT score (p=0.014) (Table 5).

Table 3. Demographic and clinical characteristics of patients in relation to comorbidities

	Comorbidities			p
	Without comorbidities	≤2	3 or more	
	n=32	n=104	n=21	
Age (yrs)	64.03±11.06	67.81±8.99	73.24±5.29	0.002
Gender (M/F)	3.57	72/32	6.00	0.209
BMI	23.78±3.62	27.08±7.04	28.59±3.86	0.010
Smoking habit				
Non smokers	4 (12.5)	17 (16.3)	4 (19.0)	0.818
Smokers	16 (50.0)	42 (40.4)	10 (47.6)	
Ex smokers	12 (37.5)	45 (43.3)	7 (33.3)	
FEV1	1.46±0.56	1.23±0.55	1.07±0.40	0.028
FVC	2.76±0.79	2.30±0.90	1.93±0.64	0.002
FVC%	75.83±15.94	69.32±18.26	59.85±14.07	0.005
CRP	26.68±30.17	20.52±25.31	40.38±40.51	0.266
Leukocyte count	9.92±2.81	8.44±2.38	10.57±4.76	0.291

BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; FVC% = percent predicted forced vital capacity; CRP = C-reactive protein

Table 4. Demographic characteristics of patients in relation to COPD Assessment Test (CAT) values

		High CAT	Low CAT		p
		n=79	n=78		
Age (yrs)		69.15±8.77	66.36±9.85	1.876	0.063
Gender (M/F)		60/19	55/23	0.347	0.556
Smoking habit	Non smoking	11	14	0.745	
	Smokers	36	32		
	Ex smokers	32	32		
Exacerbations	Rare	1	41	50.123	<0.001
	Frequent	78	37		
BMI		25.44±4.79	27.78±7.32	2.355	0.020
CRP		37.11±32.09	5.75±6.99	4.380	<0.001
Leukocyte count		9.97±3.23	7.66±2.25	3.149	0.002

BMI = body mass index; CRP = C-reactive protein

Patients with a high mMRC score had statistically more frequent exacerbations ($p<0.001$). CRP was statistically significantly higher in patients with a high mMRC score ($p<0.001$). This trend was not observed for leukocyte count according to mMRC scale. These data are shown in Table 6.

Patients with a high mMRC score had statistically significantly lower values of FEV1 (L), FEV1%,

FVC (L) and FVC% ($p<0.001$ all), and lower values of HCO₃ in arterial blood ($p=0.002$). The values of pCO₂ in arterial blood were statistically significantly higher in patients with a high mMRC score ($p=0.019$).

There was a statistically significant correlation between CAT score and mMRC dyspnea scale ($\rho=0.963$, $p<0.001$) (Fig. 1).

Table 5. Values of examined parameters compared to COPD Assessment Test (CAT) score

	High CAT n=79	Low CAT n=78		P
FEV1	0.95±0.29	1.57±0.57	8.533	<0.001
FEV1%	37.59±10.33	56.70±12.54	10.409	<0.001
FVC	1.95±0.60	2.74±0.94	6.277	<0.001
FVC%	60.02±15.13	78.87±15.13	7.806	<0.001
pH	7.42±0.06	7.43±	0.872	0.386
pO ₂	57.72±10.72	63.77±9.03	2.504	0.016
pCO ₂	45.63±13.65	40.14±5.29	2.527	0.014
HCO ₃	28.16±4.27	26.06±3.16	2.355	0.025
sO ₂	88.02±8.48	91.54±4.65	2.319	0.023

FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; FEV1% = FEV1/FVC ratio; FVC% = percent predicted forced vital capacity; pCO₂ = partial carbon dioxide pressure; HCO₃ = bicarbonate; sO₂ = oxygen saturation

Discussion

Our research showed the CRP value to correlate with the severity of the COPD clinical presentation. These results are in favor of the proven fact that COPD is a systemic inflammatory disease which primarily affects the lungs¹⁷⁻²⁰. Similar results were obtained in the studies which suggest that the reduced lung function in COPD is associated with increased levels of systemic inflammatory markers²⁰⁻²⁴. Although leukocyte




Fig. 1. Correlation between COPD Assessment Test (CAT) score and values of modified Medical Research Council (mMRC) dyspnea scale.

count is considered as a marker of systemic inflammation in COPD²⁵, in our study leukocyte count did not show any significant correlation with the severity of COPD. Several studies showed that leukocyte count was sometimes poor predictor of mortality in COPD patients²⁵.

In the present study, no statistically significant correlation was found between the level of CRP and leukocyte count and comorbidities. This result could be of great importance because it might suggest that CRP and leukocyte count are independent predictors of systemic inflammation and are not related to co-occurring diseases. Inflammatory response at the

Table 6. Demographic characteristics of patients in relation to modified Medical Research Council (mMRC) scale values

		High mMRC n=108	Low mMRC n=49		P
Age (yrs)		68.82±9.25	65.43±9.38	2.111	0.093
Gender (M/F)		79/29	36/13	0.002	0.966
Smoking habit	Non smokers	16	9		0.211
	Smokers	43	25		
	Ex smokers	49	15		
Exacerbations	Rare	4	38	90.078	<0.001
	Frequent	104	11		
BMI		26.26±6.12	27.36±6.62	1.203	0.229
CRP		30.87±31.51	6.10±8.05	3.120	0.002
Leukocyte count		9.41±3.17	7.96±2.57	1.756	0.079

BMI = body mass index; CRP = C-reactive protein

lung level to noxious agents causes systemic inflammatory changes and results in significant extrapulmonary effects that contribute to the increase of CRP and leukocyte count². In support of this interpretation, some research results indicate a higher rate of association of COPD with nutritional abnormalities, skeletal muscle dysfunction and an increased risk of diseases such as cardiovascular, metabolic, neurological and other diseases^{26,27}. Lower CAT scores were associated with lower values of CRP and leukocyte count, which supports the previously reported results²⁸. Given the fact that lower CAT scores are associated with better spirometry and blood gas analysis results^{16-18,29}, lower values of CRP and leukocyte count indicate better clinical profile of COPD, as also shown in our study.

Lower values of the mMRC dyspnea scale are associated with lower CRP and leukocyte count. The results of our study indicated that this type of relationship could only be applied to CRP level, but not to leukocyte count. These results are consistent with previously reported results³⁰⁻³². Lower values of the mMRC dyspnea scale are associated with better spirometry and blood gas analysis results in COPD. Thus, we can conclude that lower values of CRP correlate better with clinical findings in these patients. Some results of our study indicate that the value of CRP should be analyzed during acute exacerbation of COPD in order to assess the degree of systemic inflammation, as suggested from several other researches^{17,18,29}.

We also found significant correlation between CAT and mMRC dyspnea scale. Similar results have been reported from other studies^{28,33}.

The mMRC dyspnea scale and CAT provide comprehensive assessment of the overall impact of the disease on the quality of life in COPD patients. In clinical setting, it is useful to use some other parameters to assess the severity of COPD. In addition to lung function, which is an essential component for the diagnosis and defining the severity of COPD, the frequency of exacerbations, comorbidities, blood gas analysis, blood inflammatory markers (CRP and leukocyte count) should also be taken in consideration.

The CRP level in COPD exacerbation may be an independent predictor of the severity and clinical findings in these patients.

References

1. Celli BR, Macnee W, Agusti A, *et al.* Standards for diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J.* 2004;23:932-46.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. Available from: <http://www.goldcopd.com>. Accessed November 20, 2013.
3. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Global burden of disease. *Lancet.* 1997;349:1498-504. doi: 10.1056/NEJMr1201534.
4. Viegi G, Pistelli F, Sherrill DL, *et al.* Definition, epidemiology and natural history of COPD. *Eur Respir J.* 2007;30:993-1013.
5. Cazzola M, Macnee W, Martinez FJ, *et al.* Outcomes of COPD pharmacological trials: from lung functions to biomarkers. *Eur Respir J.* 2008;31:416-69. doi: 10.1183/09031936.00099306.
6. Meguro M, Barley EA, Spencer S, *et al.* Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. *Chest.* 2007;132:456-63. doi: 10.1136/thx.2010.139121.
7. Jones P, Harding G, Wiklund I, *et al.* Improving the process and outcome of care in COPD: development of a standardised assessment tool. *Prim Care Respir J.* 2009;18:208-15. doi: 10.4104/pcrj.2009.00053.
8. Jones PW, Harding G, Berry P, *et al.* Development and first validation of the COPD Assessment Test. *Eur Respir J.* 2009;34:648-54. doi: 10.1183/09031936.00102509.
9. Miravittles M, Anzueto A, Legnani D, Forstmeier L, Forgel M. Patient's perception of exacerbations of COPD – the PERCEIVE study. *Respir Med.* 2007;101(3):453-60.
10. Mazur W, Kupiainen H, Pitkaniemi J, *et al.* Comparison between the disease-specific Airways Questionnaire 20 and the generic 15D instruments in COPD. *Health Qual Life Outcomes.* 2011;9:4. doi:10.1093/rheumatology/ket265.
11. Braidó F, Baiardini I, Menoni S, *et al.* Disability in COPD and its relationship to clinical and patient-reported outcomes. *Curr Med Res Opin.* 2011;27(5):981-6. doi:10.2147/COPD.S32675.
12. Fletcher CM. Standardized questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis. *Br Med J.* 1960;2:1665.
13. Gross NJ. Chronic obstructive pulmonary disease outcome measurements: what is important? What's useful? *Proc Am Thorac Soc.* 2005;2(4):267-71.
14. Miravittles M, Ferrer M, Pont A, *et al.* Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study. *Thorax.* 2004;59(5):387-95. doi: 10.1186/1477-7525-11-147.

15. Miravittles M. Prevention of exacerbations of COPD with pharmacotherapy. *Eur Respir Rev.* 2010;19(116):119-26. doi: 10.1007/s11908-012-0255-7.
16. Anzueto A. Impact of exacerbations on COPD. *Eur Respir Rev.* 2010;19(116): 113-8. doi: 10.1183/09059180.00002610.
17. Pinto-Plata VM, Mullerova H, Toso JF, *et al.* C-reactive protein in patients with COPD, control smokers and non-smokers. *Thorax.* 2006;61:23-8. doi: 10.3399/bjgp12X654605.
18. Piehl-Aulin K, Jones I, Lindvall B, *et al.* Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. *Respiration.* 2009;78:191-6.
19. Dev D, Wallace E, Sankaran R, Cunniffe J, Govan JRW, Wathen CG, Emmanuel FX. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. *Respir Med.* 1998;92: 664-7.
20. De Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros De Fuentes M, Montejo De Garsini A, Aguirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. *Eur Respir J.* 2006;27:902-7.
21. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a meta-analysis. *Thorax.* 2004;59:574-80. doi: 10.1186/1465-9921-11-63.
22. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. *Am J Cardiol.* 2008;101:530-5.
23. Karadag F, Kirdar S, Kurul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. *Eur J Internal Med.* 2008;19:104-8. doi: 10.1007/978-1-60761-673-3_2.
24. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J.* 2003;22:672-88.
25. Moberg M, Vestbo J, Martinez G, Lange P, Ringbaek T. Prognostic value of C-reactive protein, leukocytes, and vitamin D in severe chronic obstructive pulmonary disease. *Sci World J.* 2014;2014:1-8. doi: 10.1155/2014/140736.
26. Alvar G, Agusti N. Systemic effects of chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2005;2:367-70.
27. Živković D. Effect of delays on survival in patients with lung carcinoma in Montenegro. *Acta Clin Croat.* 2014;53(4):390-8.
28. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. *Am J Respir Crit Care Med.* 2012;185(11):1218-24. doi: 10.1164/rccm.201110-1843OC .
29. Hurst JJ, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, *et al.* Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med.* 2010;363:1128-38. doi: 10.1056/NEJMoa0909883.
30. Greenberg SB, Allen MA, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2000;162:167-73. doi: 10.1136/pgmj.2004.019182.
31. Allegra L, Blasti, De Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a reevaluation of previously published data of placebo controlled randomized study. *Pulm Pharmacol Ther.* 2001;14:149-55.
32. Saches AP, Koeter GH, Gronier KH, Van Der Waaij D, Schiphuis J, Meyboom-De Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. *Thorax.* 1995;50:758-63.
33. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, *et al.* Properties of the COPD assessment test in a cross-sectional European study. *Eur Respir J.* 2011;38:29-35. doi: 10.3349/ymj.2013.54.5.1214.

Sažetak

KORELACIJA IZMEĐU C-REAKTIVNOG PROTEINA I STUPNJA TEŽINE KOPB

N. Milačić, B. Milačić, M. Milojković, S. Ljubisavljević, S. Vodopić, M. Hasanbegović i M. Đurović

Kronična opstruktivna plućna bolest (KOPB) je progresivna upalna bolest pluća obilježena sistemskom upalom. Cilj ovoga istraživanja bio je utvrditi korelaciju između parametara sistemske upale, tj. C-reaktivnog proteina (CRP) i ukupnog broja leukocita s kliničkim i parakliničkim pokazateljima bolesti. U istraživanje je bilo uključeno 157 bolesnika s KOPB koji su ambulantno i bolnički liječeni na Klinici za plućne bolesti Knez Selo Kliničkog centra Niš u razdoblju od šest mjeseci, i to tijekom faze pogoršanja KOPB. Kod svakog bolesnika simptomi KOPB su se procjenjivali pomoću testa *COPD Assessment Test* (CAT) i ljestvice mMRC-dispnjea. Uz to, procjenjivali su se parametri plućne funkcije (FEV1 i FVC), kao i acidobazni status, indeks tjelesne mase, povijest pogoršanja i komorbiditeti. Razina CRP, ali ne i leukociti, pokazala je značajnu korelaciju s težinom kliničke prezentacije prema klasifikaciji GOLD. Viša razina CRP nađena je kod bolesnika s višom klasom prema klasifikaciji GOLD, odnosno kod bolesnika s težim oblikom bolesti (niži FEV1) u egzacerbaciji ($p < 0,001$). Nije bilo statistički značajne razlike u razini CRP i broju leukocita u odnosu na komorbiditete ($p = 0,29$). Razina CRP je bila viša u bolesnika s visokim zbirom CAT i ljestvicom mMRC-dispnjea ($p < 0,001$). Korelacijska analiza je pokazala povezanost između razine CRP i ljestvice mMRC-dispnjea, ali je ta korelacija izostala između razine leukocita i vrijednosti ljestvice mMRC-dispnjea. Zaključuje se kako razina CRP tijekom faze pogoršanja KOPB može biti neovisni prediktor težine bolesti, ali i pokazatelj parakliničkih karakteristika kod ovih bolesnika.

Ključne riječi: *Plućna bolest; Kronična opstruktivna plućna bolest – dijagnostika; Kronična opstruktivna plućna bolest – klasifikacija; C-reaktivni protein; Respiratorni funkcionalni testovi; Stupanj težine bolesti, određivanje; Ankete i upitnici*